Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
Kairos Pharma, Ltd. (KAPA)
Company Research
Source: Business Wire
ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company’s randomized trial for patients receiving either apalutamide or apalutamide+ENV105 combination therapy. The additional centers allow Kairos Pharma to test ENV105 in a broader patient population to identify blood markers that could help select patients expected to benefit most from ENV105 treatment. The trial is supported by Kairos Pharma Ltd. and a grant from the National Canc
Show less
Read more
Impact Snapshot
Event Time:
KAPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KAPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KAPA alerts
High impacting Kairos Pharma, Ltd. news events
Weekly update
A roundup of the hottest topics
KAPA
News
- Kairos Pharma to Participate in The Microcap Conference in January 2025 [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma to Participate in The Microcap Conference in January 2025Accesswire
- Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- IBN Initiates Coverage of Kairos Pharma Ltd.GlobeNewswire
- Kairos Pharma Approved to Dual List on Upstream [Yahoo! Finance]Yahoo! Finance
KAPA
Sec Filings
- 12/13/24 - Form 8-K
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- KAPA's page on the SEC website